Skip to main content

Table 2 Consumption trends of antiasthmatic drugs in INN

From: Trends in the use of antiasthmatic medications in Morocco (1999–2010)

Classes/INN ATC DDD/1000H/D
1999 2006 2010
Short-acting inhaled Beta-2-mimetic     
Salbutamol R03AC02 1.70 3.42 3.94
Terbutaline R03AC03 0.12 0.04 0.06
Fenoterol R03AC04 0.06 - -
Pirbuterol R03AC08 0 - -
Orciprenaline R03AB03 0.06 - -
Systemic Beta-2-mimetic     
Salbutamol R03CC02 0.23 0.31 0.33
Terbutaline R03CC03 0.04 0.03 0.02
Long-acting inhaled Beta-2-mimetic     
Formeterol R03AC12 0.01 0.07 0.04
Salmeterol R03AC13 0.02 - -
Association Beta-2-mimetic /Glucocorticosteroids     
Fluticasone + Salmeterol R03AK06 - 1.08 6.05
Budesonide + Formeterol R03AK07 - 0.24 2.47
Inhaled Glucocorticosteroids alone     
Bedomethasone R03BA01 0.65 0.95 1.01
Budesonide R03BA02 0.03 0.01  
Fluticasone R03BA05 0.03 0.15 0.12
Injectable Xanthines     
Theophylline R03DA04 0.89 0.43 0.34
Diprophylline + Tiemonium iodure R03DA51 0.05 0.05 0,.05
  1. INN: I nternational N on-proprietary N ame / ATC : A natomical, T herapeutic and C hemical classification / DID : D DD/1000 I nhabitants /D ay.